Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand

  1. Weerawat Manosuthi
  2. Ing-orn Prasanchaimontri
  3. Suvimol Niyomnaitham
  4. Rujipas Sirijatuphat
  5. Lantharita Charoenpong
  6. Katherine Copeland
  7. Tim R. Cressey
  8. Phongpan Mokmued
  9. Kulkanya Chokephaibulkit

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (C min ) above EC 50 (9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2022.03.09.22271220: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: This study was approved by the Siriraj Institutional Review Board (approval no. Si 434/2020) and registered at Thaiclinicaltrials.org (No. TCTR20200514001).
    Sex as a biological variablenot detected.
    RandomizationHere we report the results of a pharmacokinetic sub-study of FPV nested within a prospective randomized clinical trial of adults with symptomatic SARS-CoV-2 infection without pneumonia.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    A limitation of this study was the ability to associate clinical or virologic outcomes with FPV drug exposure. Overall, this study provides novel data on the pharmacokinetics of FPV and its metabolite in adults with symptomatic SARS-CoV-2 infection without pneumonia and can help to guide dosing recommendations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2022.03.09.22271220v1 on medRxiv